This Article Full Text (PDF) All Versions of this Article: 0003319707306144v1 59/5/542    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (3) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Isma, N. Articles by Gottsäter, A. Search for Related Content PubMed PubMed Citation Articles by Isma, N. Articles by Gottsäter, A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Social Bookmarking                         What's this?

Lipid-Lowering Therapy is Related to Inflammatory Markers and 3-Year Mortality in Patients With Critical Limb Ischemia

University of Lund, Department of Vascular Diseases, Malmö University Hospital, Malmö, Sweden, nazim.isma{at}skane.se

Jamal Barani, MD, PhD

University of Lund, Department of Vascular Diseases, Malmö University Hospital, Malmö, Sweden

Ingrid Mattiasson, MD, PhD

University of Lund, Department of Vascular Diseases, Malmö University Hospital, Malmö, Sweden

Bengt Lindblad, MD, PhD

University of Lund, Department of Vascular Diseases, Malmö University Hospital, Malmö, Sweden

Anders Gottsäter, MD, PhD

University of Lund, Department of Vascular Diseases, Malmö University Hospital, Malmö, Sweden

To evaluate relationships between lipid-lowering therapy, inflammation, and 3-year mortality in critical limb ischemia (CLI), 259 consecutive CLI patients underwent evaluation of medication, tumor necrosis factor-, interleukin-6 (IL-6), neopterin, high-sensitivity C-reactive protein (hs-CRP), 8-epi-PGF₂ , and endothelin-1. Mortality was assessed after 3 years. Sixty-one patients (24%) were on lipid-lowering therapy and 59 patients (97%) on statins. Patients on lipid-lowering therapy were younger and showed lower low-density lipoprotein cholesterol, hs-CRP, and IL-6 levels than patients without therapy. Three-year survival was higher among patients on lipid-lowering therapy. In logistic regression, the effect of lipid-lowering therapy on 3-year survival was significant with inflammatory markers entered into the model one by one but disappeared when all inflammatory markers were entered into the model together. In conclusion, hs-CRP and IL-6 levels were lower and 3-year survival was higher in CLI patients on lipid-lowering therapy.

Key Words: critical limb ischemia • inflammation • risk factors • lipid lowering • statin

This version was published on October 1, 2008

Angiology, Vol. 59, No. 5, 542-548 (2008)
DOI: 10.1177/0003319707306144


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				I. Bountouris, K. I. Paraskevas, M. Koutouzis, V. Tzavara, N. Nikolaou, A. Nomikos, C. Barbatis, V. Andrikopoulos, D. P. Mikhailidis, M. Andrikopoulou, et al. Serum Leptin Levels in Patients Undergoing Carotid Endarterectomy: A Pilot Study Angiology, December 1, 2009; 60(6): 698 - 704. [Abstract] [PDF]

				K. I. Paraskevas, C. Psathas, T. Dragios, D. G. Chatzis, D. P. Mikhailidis, and Z. S. Kyriakides The Impact of Novel Treatment Modalities on the Therapeutic Approach of Cardiovascular Diseases Angiology, February 1, 2009; 60(1): 5 - 7. [PDF]

				K. I. Paraskevas, N. Bessias, T. T. Papas, V. Andrikopoulos, and D. P. Mikhailidis Is High-sensitivity C-reactive Protein Associated With Subclinical Peripheral Atherosclerosis? Angiology, February 1, 2009; 60(1): 8 - 11. [PDF]